secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001826667-25-000115
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M
------------------------------------------------------------------------------

- Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.
- Operating loss improved to $7.3M from $8.2M; net loss $9.0M ($0.27 diluted EPS loss).
- Reaffirmed FY2025 revenue growth at least 50%; cash $26.5M, runway to positive adj. EBITDA H1 2026.
- Launched TriNav FLX for tortuous vessels; early sales exceeded internal projections.
- Simplified capital structure via exchange of Series A Preferred stock completed post-quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/0001826667-25-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/tlsi-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001826667-25-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer